Insomnia
Conditions
Keywords
sleep, arousal, stress, cortisol, catecholamines
Brief summary
The purpose of this study is to evaluate the change in measures of physiological arousal before and after behavioral treatment of insomnia.
Detailed description
There is good evidence that physiological arousal, associated with sustained activation of the hypothalamic-pituitary axis and the sympathetic nervous system, is an underlying cause of chronic insomnia. Accordingly, relaxation-related treatments that address elevated cognitive and somatic arousal have been effective for insomnia. Previous studies have documented the effectiveness of behavioral treatments in reducing activation of the hypothalamic-pituitary axis and the sympathetic nervous system and in the treatment of specific medical disorders including insomnia. The aim of this proposal is to evaluate the hypothesis that improvements in chronic psychophysiological insomnia following a behavioral treatment are tightly associated with reduction of arousal in the hypothalamic-pituitary axis, as measured by plasma cortisol, and in the sympathetic nervous system, as measured by urinary catecholamines. Objective measures of sleep will be derived from polysomnographic recordings from subjects randomized into a 10-week active behavioral treatment or placebo behavioral control treatment group. Continuous 24-hour evaluation of cortisol and catecholamines will be performed under controlled laboratory conditions before and after treatment. We anticipate significant reductions in cortisol and catecholamines in the active treatment group as compared with the control group. We also anticipate that the active treatment will yield reductions in related measures of arousal including heart rate, autonomic arousal (as determined from heart rate variability), and body temperature. Given reported evidence that melatonin levels are chronically low in insomnia we anticipate an increase in the sleep-related hormone melatonin in the yoga treatment group. If achieved, these results will provide a novel demonstration of a reduction of arousal in a behavioral insomnia treatment and a behaviorally enhanced melatonin secretion under controlled laboratory conditions.
Interventions
BEHAVIORALmind body treatment
regulation of attention, respiration and posture
BEHAVIORALdesensitization
mentation on insomnia behaviors and cognitive activity
Sponsors
National Center for Complementary and Integrative Health (NCCIH)
Brigham and Women's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
21 Years to 59 Years
Healthy volunteers
No
Inclusion criteria
* primary insomnia for 6 months * average total wake time \>60 minutes and sleep efficiency \<80% * at least 1 daytime complaint due to insomnia * adequate opportunity and circumstance for sleep
Exclusion criteria
* current psychiatric condition * medical condition that interferes with sleep * pregnancy * rotating shift work, night work or transcontinental travel during study * anticipated major life stressor over the course of the study * use of hypnotic or psychoactive medications * no idiopathic or sleep state misperception insomnia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective sleep efficiency | pretreatment, posttreatment |
| plasma cortisol | pretreatment, posttreatment |
| plasma melatonin | pretreatment, posttreatment |
| urinary catecholamines | pretreatment, posttreatment |
| heart rate variability | pretreatment, posttreatment |
| subjective sleep efficiency | pretreatment, during treatment, posttreatment, followup |
Secondary
| Measure | Time frame |
|---|---|
| EEG | pretreatment, posttreatment |
| subjective mood | pretreatment, during treatment, posttreatment, followup |
| depression | pretreatment, during treatment, posttreatment, followup |
| anxiety | pretreatment, during treatment, posttreatment, followup |
| actigraphy | pretreatment, posttreatment |
Countries
United States
Outcome results
None listed